Latest filing published 13 May 2025 for GERON CORP, €14k. Read the official filing
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
Filings by V. Bryan Lawlis span 2 companies, the busiest being Biomarin Pharmaceutical Inc and Geron Corp. In total, 50 filings cover trades dated from 6 June 2016 to 9 May 2025.
The open-market side counts 1 purchase for €14k alongside 19 sales for €5.6M. Sales outweigh purchases by €5.6M. Open-market purchases are the filings investors watch most closely, because the insider pays for the shares out of pocket. Outside the open market, there are 8 share grants and 21 option exercises. 2025 to date brings 1 purchase and no sales.
Most recently, on 13 May 2025, the filings show an open-market purchase worth €14k in Geron Corp. Filings reach the SEC (Form 4) feed a median of 2 days after the trade. US insiders must file a Form 4 within two business days of a trade. Keep in mind that insiders sell for many reasons unrelated to the outlook, from tax bills to estate planning. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
9 of 9 declarations